​Atlanta, GA
April 25-26, 2012

This two-day workshop held in Atlanta, GA was sponsored by the Association of Public Health Laboratories (APHL), U.S. Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE), with partial support from the Marler Clark law firm. The Forum assembled subject matter experts representing various fields, industries and agencies to discuss the complex issues of increasing culture independent methods in clinical diagnostic laboratories.  The participatory meeting involved panels and breakout sessions where participants presented, discussed and brainstormed potential solutions to address the anticipated impacts of culture independent clinical diagnostics on surveillance activities.  The Forum focused on bacterial enteric (primarily foodborne) diseases and included  similar surveillance issues that other areas of infectious disease (e.g. sexually transmitted diseases) have experienced or will experience in the future due to testing technology shifts.

This page links to presentations that have been authorized to be posted on this Web site. Duplication is not authorized without the express written permission of the authors.

Culture Independent Diagnostics Forum Summary

Wednesday, April 25

Welcome to the Forum - Dr. Rima Khabbaz, CDC

Forum Overview - Dr. John Besser

Panel 1 Sessions - Outbreak Detection and Investigation
- Moderated by Dr. Rob Tauxe, CDC

Foodborne Disease Outbreak Detection and Investigation Impacts
- Dr. Ian Williams, CDC

Public Health Impacts on Non-Foodborne Diseases
- Dr. Joanne Bartkus, Minnesota Department of Health

Toxin-based Surveillance of Shiga Toxin-producing E. coli Infection—The German Experience
- Dr. Dirk Werber, Robert Koch Institute

Panel 2 Sessions - Burden/Attribution/Trends
- Moderated by Dr. Elaine Scallan, University of Colorado - Denver

Sporadic Enteric Disease—We are the 90%: Reducing the Burden of Disease in a Culture-independent World
- Dr. Rajal Mody, CDC

Surveillance for Antimicrobial Resistance in the Absence of Culture
- Dr. Jean Patel, CDC

Pathogen Testing in a Public Health Setting: FSIS Perspective
- Dr. David Goldman, USDA/FSIS

The Importance of Cultures in FDA’s Regulatory Science Program
- Dr. Eric Brown, FDA-CFSAN

Panel 3 Sessions - Stakeholder Perspectives
- Moderated by Dr. Hugh Maguire, Colorado Department of Public Health

A Physician’s Perspective
- Dr. Marguerite Neill, Memorial Hospital of Rhode Island

A Clinical Laboratory Perspective: Patient Benefit vs. Public Good
- Dr. Vicki Baselski, University of Tennessee Health Science Center

PCR, EIA, and MALDI: Oh My!!
- Dr. Robyn Atkinson, Utah Unified State Laboratories

The ‘Culture’ of Forensic Science: Application of Microbiological Culture to Forensic Attribution
- Dr. Douglas Anders, FBI Hazardous Materials Science Response Unit

The Regulatory Food Safety Laboratory Perspective on Culture Independent Diagnostic Assays
- Dan Rice, NY State Department of Agriculture & Markets

The Consumer Advocacy Perspective
- Dr. Barbara Kowalcyk, Center for Foodborne Illness Research & Prevention

Panel 4 Sessions - Scientific, Legal, and Regulatory Perspectives
- Moderated by Dr. Eric Brown, FDA-CFSAN

Charting a Path for Public Health – Where is Technology At? Where is it Going?
- Dr. Nancy Miller, Boston Medical Center

Current State of Metagenomics: Diarrhea
- Dr. Colin Stine, University of Maryland

Food Enforcement Perspectives
- Ms. Priya Rathnam, FDA-CFSAN

Clearance/Approval of Diagnostic Devices: Warnings/Limitations in a Package Insert
- Dr. Uwe Scherf, FDA-CDRH 

Thursday, April 26

Breakout Group A: Regulatory and Device Industry Strategies
- Moderated by Patricia Griffin

Breakout Group B: Clinical and Public Health Practice
- Moderated by Raj Mody

Breakout Group C: Strategies 1—Culture-independent pathogen characterization assay development (strain, virulence, susceptibility, etc.)
- Moderated by Efrain Ribot and Patti Fields

 Breakout Group D: Strategies 2—Culture-independent pathogen characterization assay development (strain, virulence, susceptibility, etc.) plus strategies for susceptibility surveillance
- Moderated by Barbara Mahon and Eric Brown

Group E: Novel approaches, known but unproven technologies or processes
- Moderated by Joanne Bartkus and Peter Gerner-Smidt 


For more information contact, Kristy Kubota, MPH Senior Specialist, PulseNet Program, 240.485.2720, kristy.kubota@aphl.org